151 results on '"Rybicki, Lisa A."'
Search Results
2. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
3. Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
4. The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma
5. Venous Thromboembolism Is Associated with Inferior Survival after Allogeneic Hematopoietic Cell Transplant
6. Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma
7. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
8. Comparison of the Prognostic Value of Risk Assessment Tools in Allogeneic Hematopoietic Cell Transplantation
9. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease
10. Methylnaltrexone for Refractory Opioid-Induced Constipation in Hospitalized Cancer Patients—A Highly Effective Treatment (F415A)
11. Decreased Incidence of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
12. Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design
13. Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients
14. Tu2015 GASTROINTESTINAL AND HEPATIC MANIFESTATIONS OF PTEN HAMARTOMA TUMOR SYNDROME IN CHILDREN: A RETROSPECTIVE REVIEW FROM A LARGE MEDICAL CENTER WITH A PTEN MULTIDISCIPLINARY TEAM
15. Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation
16. Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome in the Contemporary Era
17. Measuring Patient-Reported Outcomes (PROs) in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients
18. Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation
19. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
20. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma
21. Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study
22. Comparison of the Tolerability of Busulfan, Cyclophosphamide, Etoposide (BuCyVP) Versus Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) for Autologous Hematopoietic Cell Transplant (AHCT) in Hodgkin Lymphoma
23. Post-Transplant Radiation Had No Impact on Survival in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma
24. Evaluation of Corticosteroids for Engraftment Syndrome (ES) Prophylaxis in Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) with High-Dose Melphalan (MEL)
25. Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome
26. Day 100 Risk Assessment Tool Predicts 1-Year Mortality after Allogeneic Hematopoietic Cell Transplantation
27. Pharmacokinetic-Guided Therapeutic Dose Monitoring (TDM) of Busulfan Reduces Relapse of Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplantation (ASCT)
28. Conditional Survival in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation
29. Time to Transplantation (TTT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) Is Comparable Among Adolescent and Young Adults (AYAs) and Older Adults
30. A Telephone Call Reminder to Decrease the No-show Rate in an Outpatient Palliative Medicine Clinic
31. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
32. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation
33. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell Transplantation
34. Propensity Matched Analysis of Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant Recipients
35. PREDICTING MORTALITY IN PATIENTS WITH CANCER AND ATRIAL FIBRILLATION
36. Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation Outcomes
37. Trypan Blue Viability as an Alternative to CD34-Specific Viability for Frozen-Thawed Hematopoietic Progenitor Cell Products to Meet FACT and AABB Standards
38. Complication Rates and Resource Utilization in the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation (Allo HCT) Using Related Haploidentical Donors (Haplo) or Umbilical Cord Blood (UCB)
39. Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes
40. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
41. Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation
42. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population
43. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
44. Identifying predictors for bleeding in hospitalized cancer patients: A cohort study
45. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study
46. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia
47. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
48. Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes
49. Association of Socioeconomic Status (SES) with Chronic Graft-Versus-Host Disease (cGVHD) Outcomes
50. P204 How Often Is A Laxative Prescribed at the Initiation of Opioid Therapy and Are There Differences in Prescribing Patterns Between Palliative Medicine Physicians and Oncologists?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.